Article
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Blood - 12 Mar 2020
DiNardo C D, Tiong I S, Quaglieri A, MacRaild S, Loghavi S, Brown F C, Thijssen R, Pomilio G, Ivey A, Salmon J M, Glytsou C, Fleming S A, Zhang Q, Ma H, Patel K P, Kornblau S M, Xu Z, Chua C C, Chen Xufeng, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang D C S, Roberts A W, Majewski I J, Konopleva M, Wei A H
Abstract excerpt
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based combinations to identify molecular correlates of durable remission, response followed by relapse (adaptive resistance), or refractory disease (primary resistance). High...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.